These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 10938035)

  • 1. Cost effectiveness of multiple sclerosis drugs remains unknown.
    MacDonald R
    BMJ; 2000 Aug; 321(7258):399. PubMed ID: 10938035
    [No Abstract]   [Full Text] [Related]  

  • 2. The multiple sclerosis risk sharing scheme.
    Scolding N
    BMJ; 2010 Jun; 340():c2882. PubMed ID: 20522661
    [No Abstract]   [Full Text] [Related]  

  • 3. Commentary: Scheme has benefited patients.
    Compston A
    BMJ; 2010 Jun; 340():c2707. PubMed ID: 20522660
    [No Abstract]   [Full Text] [Related]  

  • 4. Commentary: Outcome measures were flawed.
    Ebers GC
    BMJ; 2010 Jun; 340():c2693. PubMed ID: 20522659
    [No Abstract]   [Full Text] [Related]  

  • 5. How will we manage?
    Carroll VS
    J Neurosci Nurs; 2011 Feb; 43(1):1-2. PubMed ID: 21338039
    [No Abstract]   [Full Text] [Related]  

  • 6. Continuing the multiple sclerosis risk sharing scheme is unjustified.
    McCabe C; Chilcott J; Claxton K; Tappenden P; Cooper C; Roberts J; Cooper N; Abrams K
    BMJ; 2010 Jun; 340():c1786. PubMed ID: 20522655
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of chronic hepatitis B in india: what is the cost of life?
    Anand AC
    Natl Med J India; 2002; 15(6):317-9. PubMed ID: 12540063
    [No Abstract]   [Full Text] [Related]  

  • 8. [Multiple sclerosis: cost of the illness].
    Tissot E; Woronoff-Lemsi MC
    Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 2):1169-74. PubMed ID: 11787352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Assessment of the high cost drug program on an example of the interferon treatment of multiple sclerosis].
    Vlasov IaV; Dolgikh GT; Dolgilh TA; Kurapov MA; Nilov AI; Tarasova SV; Churakov MV; Khivintseva EV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(2 Pt 2):66-73. PubMed ID: 23528597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Will public health survive QALYs?
    Heller JG
    Can J Clin Pharmacol; 2002; 9(1):5-6. PubMed ID: 11919640
    [No Abstract]   [Full Text] [Related]  

  • 11. Shared scheme for assessing drugs for multiple sclerosis: dealing with uncertainties about cost effectiveness of treatments is difficult problem.
    Chadwick D; Gray R
    BMJ; 2003 May; 326(7400):1212-3. PubMed ID: 12775632
    [No Abstract]   [Full Text] [Related]  

  • 12. Interferon beta, PHARMAC, and political directives: in the best interests of people with multiple sclerosis?
    McNaughton H; Kayes N; McPherson K
    N Z Med J; 2006 Apr; 119(1232):U1939. PubMed ID: 16633398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis.
    Choi HK; Seeger JD; Kuntz KM
    J Rheumatol; 2002 Jun; 29(6):1156-65. PubMed ID: 12064828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MS Drugs: Expensive, Often Lifelong, and Not Cost Effective.
    Huff C
    Manag Care; 2018 Oct; 27(10):30-34. PubMed ID: 30309445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Early multiple sclerosis therapy in the effects of public health economics].
    Rieckmann P
    Med Klin (Munich); 2001 Sep; 96 Suppl 1():17-21. PubMed ID: 11603111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost of medication and the cost of treatment are not the same thing for multiple sclerosis.
    Fragoso YD
    Arq Neuropsiquiatr; 2013 Aug; 71(8):499-500. PubMed ID: 23982003
    [No Abstract]   [Full Text] [Related]  

  • 17. Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden.
    Kobelt G; Berg J; Lindgren P; Jonsson B; Stawiarz L; Hillert J
    Mult Scler; 2008 Jun; 14(5):679-90. PubMed ID: 18566030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The efficiency and cost-utility ratio of interferon beta in the treatment of multiple sclerosis in Andalusia].
    Medina-Redondo F; Herrera-Carranza J; Sanabria C; Navarro G; García-Moreno JM; Gamero-García MA; Páramo MD; Ruiz-Peña JL; Izquierdo G
    Rev Neurol; 2004 Jul 1-15; 39(1):1-6. PubMed ID: 15257519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Costs of treatment in patients with moderate to severe plaque psoriasis: economic analysis in a randomized controlled comparison of methotrexate and cyclosporine.
    Opmeer BC; Heydendael VM; De Borgie CA; Spuls PI; Bossuyt PM; Bos JD; De Rie MA
    Arch Dermatol; 2004 Jun; 140(6):685-90. PubMed ID: 15210458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Price increases and new drugs drive increased expenditures for multiple sclerosis.
    Schafer JA; Gunderson BW; Gleason PP
    J Manag Care Pharm; 2010; 16(9):713-7. PubMed ID: 21067257
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.